Change from NUB to DRG funding for two medical procedures in Germany

06

Dec 2018

In October of 2018, InEK has published the list of the devices, previously (in 2018) eligible for innovation funding via NUB (received status 1), and which will be integrated into DRG payment system since 2019. Only two devices will be transferred into the DRG catalogue:

  • Radionuclide therapy with Lutetium 177-labeled prostate-specific membrane antigen (PSMA) in prostate cancer – treatment will be reimbursed via DRG M10B “Radioligandentherapie mit Lutetium-177-PSMA-Liganden”
  • Percutaneous mitral valve anullorrhopathy with clasp (was applicable to devices like Carillon from Cardiac Dimensions) – device will be reimbursed via DRG F98C “Komplexe minimalinvasive Operationen an Herzklappen ohne minimalinvasiven Eingriff an mehreren Herzklappen [...] ohne sehr komplexen Eingriff”

See full details in German here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

06

Jun 2023

Director of MTRC Oleg Borisenko participated in the session “Innovative Payment Schemes (IPSs) in Europe: springboard for innovation?” at the Med Tech Forum in Dublin on the 31st of May 2023. The section was moderated by Rachele Busca (Director, HTA and Real-World Evidence, EMEACLA, Edwards Lifesciences) and panelists included Daniel Bamford (Deputy Director, Medtech and Digital, Innovation, Research and Life Sciences, NHS England) and Louisa Stüwe (Ministerial eHealth Delegation, Ministry of Health and Prevention, France). Oleg presented the summary of the report on innovative payment schemes for medical technologies, commissioned in 2022 by the European industry association Med Tech Europe to MTRC. We present a summary of the presentation.

Read more

02

Jun 2023

On May 15, 2023, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions, recommending the transfer to standard care for another three completed projects. The projects relate to controlling drug prescriptions in outpatient settings, evaluating the effectiveness of outpatient extensive stuttering therapy in primary school children, and the efficacy of cross-sectoral care models in psychiatry.

Read more

30

May 2023

On April 5, 2023, the Innovation Committee at the Federal Joint Committee (G-BA) announced the selection of thirty-five applications for Innovation Funding of healthcare research projects were accepted. A total of 231 applications were received in response to the funding announcement of June 27, 2022 (changed on September 20, 2022), and thirty-five of them were accepted.

Read more

24

May 2023

Between late April and May 2023, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 47 health apps are currently available in the DiGA Directory, and six health apps were delisted from the Directory.

Read more

08

May 2023

On April 14, 2023, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2023 RIHN list.

Read more